6
Views
10
CrossRef citations to date
0
Altmetric
Original Article

Dual and Triple Therapy Regimens of Antisecretory Agents and Antibiotics for the Eradication of Helicobacter pylori: An Overview

, &
Pages 3-9 | Published online: 08 Jul 2009
 

Abstract

Background: Studies evaluating therapeutic regimens that combine antisecretory agents with antibiotics for the eradication of H. pylori have reported significant variations in efficacy.

Methods: We reviewed the published literature to compare H. pylori eradication rates in patients treated with either omeprazole, ranitidine bismuth citrate (RBC), or ranitidine plus metronidazole combined with either amoxicillin or clarithromycin.

Results: Wide variations in H. pylori eradication rates have been reported with omeprazole plus either amoxicillin (0–100%) or clarithromycin (42–88%). Eradication rates ranging from 45% to 89% and from 74% to 94% have been reported with RBC plus either amoxicillin or clarithromycin, respectively. Eradication rates ranging from 48% to 90% have been reported with ranitidine plus metronidazole and amoxicillin and one study reported an eradication rate of 95% with ranitidine plus metronidazole and clarithromycin.

Conclusions: Well-controlled trials with ranitidine bismuth citrate plus clarithromycin suggest that this combination may provide the most consistent and effective regimen for the eradication of H. pylori infection.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.